Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics Presents Data Demonstrating Immune Response Targeting Cancer Stem Cells
November 26th, 2008
ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC)(IMUC), a biotechnology company, presented data showing an immunological response against cancer stem cells (CSCs) derived from brain cancer, specifically glioblastoma. It has been demonstrated in the last few years that CD-133, a cell surface marker, is present on many different types of cancer stem cells and should therefore make an excellent target for ICT-121, the company's cancer stem cell vaccine product candidate, which is specifically designed to generate a T cell response against CD-133. CD-133-positive cancer stem cells continue to renew themselves, therefore causing tumors to proliferate and grow. They are...
Source: Vaccine Weekly (2008-11-26)
|
